Halozyme Therapeutics | HALO - Operating Expenses


Halozyme Therapeutics reported $211.07M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 266.6M 23.72M Dec/2025
Agios Pharmaceuticals USD 141.54M 11.8M Dec/2025
Alnylam Pharmaceuticals USD 965.32M 84.27M Dec/2025
Amarin USD 51.37M 14.6M Sep/2025
Amgen USD 5.9B 773M Dec/2025
Baxter International USD 3.19B 554.4M Dec/2025
Cara Therapeutics USD 4.96M 2.38M Mar/2025
Cytokinetics USD 196.12M 27.43M Dec/2025
DBV Technologies USD 37.05M 4.06M Sep/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Esperion Therapeutics USD 67.66M 3.6M Sep/2024
Halozyme Therapeutics USD 211.07M 74.73M Dec/2025
Intrexon USD 61.56M 26.1M Jun/2024
Ionis Pharmaceuticals USD 418M 101.1M Dec/2025
MannKind USD 119.64M 56.29M Dec/2025
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Nektar Therapeutics USD 85.09M 109.3M Sep/2025
Pfizer USD 12.91B 79.89B Dec/2025
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
United Therapeutics USD 804.8M 5.79B Dec/2025
Vanda Pharmaceuticals USD 466M 20.33M Sep/2025